Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,356 result(s) found. Displaying page 1,900 of 2,218.
    «« First « Previous 1896  1897  1898  1899  1900  1901  1902  1903  1904  Next» Last»»
    EudraCT Number: 2012-004313-13 Sponsor Protocol Number: 20121001 Start Date*: 2013-01-22
    Sponsor Name:Skåne University Hospital, Dept of Oncology
    Full Title: A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.
    Medical condition: Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard Octreoscan
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002290-25 Sponsor Protocol Number: FEBATRIC Start Date*: 2022-02-10
    Sponsor Name:Nadační fond Donatio intensivistam
    Full Title: Faecal bacteriotherapy for postantibiotic diarrhoea in critically ill patients
    Medical condition: Postantibiotic diarrhoea
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002862-15 Sponsor Protocol Number: BupivacTons20 Start Date*: 2021-03-03
    Sponsor Name:Nordland Hospital. Bodø. Dep of Surgery
    Full Title: Can topical anaesthesia with bupivacaine reduce pain after tonsillectomy?
    Medical condition: Local pain after tonsillectomy, both at rest and during swallowing. Assessed by self-reporting at 1, 2, 3, 4, 5, 6 hours and 1,2,4 and 6 days after surgery.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004163-39 Sponsor Protocol Number: OV126b Start Date*: 2017-06-30
    Sponsor Name:ARCAGY-GINECO
    Full Title: A randomized, open-label, multicentric phase II trial of PEMBROLIZUMAB (Ketruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amen...
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004381-25 Sponsor Protocol Number: 1608170 Start Date*: 2017-11-24
    Sponsor Name:CHU de Saint-Etienne
    Full Title: Study of the impact of a targeted decolonization of S. aureus in persistent carriers on the occurrence of S. aureus infections in hemodialysis patients
    Medical condition: Hemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022103 10066622 Chronic hemodialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015720-28 Sponsor Protocol Number: CCRG 09-003 Start Date*: 2009-12-18
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial.
    Medical condition: Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10046859 Vaccination LLT
    12.0 10024329 Leukemia LLT
    12.0 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000547-24 Sponsor Protocol Number: CCRG11-001 Start Date*: 2012-02-27
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study
    Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016502-16 Sponsor Protocol Number: PML_DOC_0905_/_ISSSYMB0020 Start Date*: 2009-12-02
    Sponsor Name:University Hospital Antwerp : Department Respiratory Medicine
    Full Title: A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbo...
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001505-24 Sponsor Protocol Number: 2012-001505-24 Start Date*: 2013-02-25
    Sponsor Name:Academic Medical Center
    Full Title: Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses
    Medical condition: deep vein thrombosis pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066529 Deep vein thrombosis recurrent LLT
    21.1 100000004855 10066738 Recurrent pulmonary embolism LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) IE (Completed) BE (Completed) ES (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000984-29 Sponsor Protocol Number: AGO/2011/003 Start Date*: 2011-04-07
    Sponsor Name:Ghent University Hospital
    Full Title: Prospectieve vergelijkende studie tussen verschillende tumescentie technieken bij endoveneuze ablatie behandeling voor varices
    Medical condition: Patiënten die behandeld worden voor endoveneuze ablatio van een oppervlakkig veneuze insufficiëntie
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022572-32 Sponsor Protocol Number: AGO/2010/005 (A-48-52030-740) Start Date*: 2011-05-10
    Sponsor Name:Ghent University Hospital
    Full Title: Invloed van Somatuline® autogel 120mg op post-operatieve drainage na rectumresectie voor rectumcarcinoom
    Medical condition: Patiënten die een rectumresectie ondergaan voor rectumcarcinoom.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003836-31 Sponsor Protocol Number: AGO/2006/007 Start Date*: 2006-09-06
    Sponsor Name:University Hospital Gent
    Full Title: A protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximab
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042953 Systemic sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002762-12 Sponsor Protocol Number: SJ-674 Start Date*: 2021-12-07
    Sponsor Name:Zealand University Hospital
    Full Title: The prevalence of bile acid diarrhéa and the effect of budesonid on the bile acid homeostasis in patients with microscopic colitis
    Medical condition: Microscopic colitis Bile acid diarrhea
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004909-32 Sponsor Protocol Number: 5798002749939 Start Date*: 2021-02-16
    Sponsor Name:Department of Oncology
    Full Title: Can Eribulin enhance the effect of subsequent endocrine therapy?- a phase 2 study for patients with ER positive HER2 normal metastatic breast cancer
    Medical condition: Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001211-75 Sponsor Protocol Number: D0816C00002 Start Date*: 2013-11-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Comple...
    Medical condition: BRCA Mutated Platinum Sensitive Relapse (PSR) high grade Serous Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Ongoing) FR (Ongoing) PL (Completed) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002368-30 Sponsor Protocol Number: D967MC00001 Start Date*: 2021-04-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activ...
    Medical condition: Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004770-25 Sponsor Protocol Number: D7310C00001 Start Date*: 2020-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head an...
    Medical condition: Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) DE (Trial now transitioned) BE (Completed) AT (Completed) BG (Completed) PL (Completed) FR (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015970-36 Sponsor Protocol Number: D0810C00041 Start Date*: 2010-02-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Pa...
    Medical condition: Serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001574-29 Sponsor Protocol Number: D967VC00001 Start Date*: 2020-10-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
    Medical condition: Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004846-25 Sponsor Protocol Number: Pfizer-Prevenar13-2015 Start Date*: 2016-07-15
    Sponsor Name:Maastricht University
    Full Title: Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders
    Medical condition: Familial hypercholesterolemia Niemann-Pick disease type B (NPB) Niemann-Pick disease type C (NPC) Partial lipodystrophy in children and adults
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1896  1897  1898  1899  1900  1901  1902  1903  1904  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 20 21:02:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA